|Articles|May 27, 2016

Valeant Rejected Takeda Bid

May 27, 2016.

Reuters reports that Valeant Pharmaceuticals rejected a joint takeover offer from Japan's Takeda and TPG Capital Management this spring.

The offer was reportedly made a few weeks before Joseph Papa took over as Valeant's new chief executive in April.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Rathi Suresh, PhD, Vice President, Analytics, Komodo Health.

The AI Force Multiplier: How AI Is Leveling the Playing Field for Small and Mid-Size Biotech

ByRathi Suresh, PhD

February 5th 2026

From OR to Office: How Workflow Change and AI Are Reshaping MedTech Adoption

ByNicholas Jacobus,Dave Carey ,Michael Monovoukas

February 3rd 2026

Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat

ByMike Hollan

January 26th 2026

The Inflection Point of Pharma and AI: Q&A with Anders Romare

ByNicholas Jacobus,Anders Romare

January 21st 2026

To Build or to Buy: Determining Your AI Path

ByRathi Suresh, PhD

January 20th 2026

Valeant Rejected Takeda Bid

Newsletter

Related Content

The AI Force Multiplier: How AI Is Leveling the Playing Field for Small and Mid-Size Biotech

From OR to Office: How Workflow Change and AI Are Reshaping MedTech Adoption

Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat

The Inflection Point of Pharma and AI: Q&A with Anders Romare

To Build or to Buy: Determining Your AI Path

Trending on PharmExec

FDA to Take Action Against Mass-Marketing of Illegal Copycat Drugs: Report

Everything to Know About TrumpRx in 2026

Novo Nordisk Launches First Super Bowl Commercial for Wegovy Pill

Pharmaceutical Executive Daily: The Launch of TrumpRx